Abstract
Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas and anogenital warts. Severe systemic side effects associated to imiquimod 5% cream are rare, although few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated to topical treatment with imiquimod of two superficial basal cell carcinomas.
Reference10 articles.
1. Cantisani C, Lazic T, Richetta AG, Clerico R, Mattozzi C, Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012 Jan;6:65-9.
2. Nanda J, Bermudez R. Imiquimod. 2022 Jul 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
3. Camacho Molina A, Alarcón Manoja E, Corzo Gilabert JR, García Gil D. Erythema multiforme induced by topical imiquimod. Emergencias. 2020;32:219.
4. Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021 Aug 28;57(9):895. doi: 10.3390/medicina57090895. PMID: 34577817; PMCID: PMC8472007.
5. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan;129(1):92-6.